Current Report Filing (8-k)
October 06 2016 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 6, 2016
MATINAS BIOPHARMA HOLDINGS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
|
|
46-3011414
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
ID Number)
|
1545 Route 206 South, Suite 302
Bedminster, New Jersey
|
|
07921
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (908) 443-1860
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
Matinas BioPharma Holdings, Inc. (the “Company”)
intends to use a slide presentation in connection with an investor update call to take place on Thursday, October 6, 2016 and thereafter
at various investor meetings. The slide presentation is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2
of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act
or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
This Current Report on Form 8-K, including
exhibit 99.1, contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines,
market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or
conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking
statements include words such as “expects,” “anticipates,” “intends,” “plans,“
“could”, “believes,” “estimates” and similar expressions. These statements involve known and
unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results
expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties,
including, but not limited to, our ability to successfully complete research and further development and commercialization of our
product candidates; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including
the additional capital which will be necessary to complete the clinical trials for our product candidates; the uncertainties inherent
in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual
property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape
or the imposition of regulations that affect the Company's products; and the other factors listed under “Risk Factors”
in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Prospective investors are cautioned not to place undue reliance
on such forward-looking statements, which speak only as of the date of this presentation. Matinas does not undertake any obligation
to release publicly any revisions to such forward-looking statement to reflect events or circumstances after the date hereof or
to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage
and are not currently available for sale or use.
All forward-looking statements are expressly
qualified in their entirety by this cautionary notice. You are cautions not to place undue reliance on any forward-looking statements,
which speak only as of the date of this Current Report on Form 8-K. We have no obligation, and expressly disclaim any obligation,
to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Item 9.01. Financial Statements and Exhibits
Exhibit
|
|
Description
|
99.1
|
|
Slide Presentation
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
MATINAS BIOPHARMA HOLDINGS, INC.
|
|
|
Date: October 6, 2016
|
|
/s/ Roelof Rongen
|
|
|
Roelof Rongen, Chief Executive Officer
|
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2023 to Apr 2024